Andrew Armanino - Jun 9, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Director
Signature
/s/ Mark Heinen, Attorney-in-Fact
Stock symbol
BTTX
Transactions as of
Jun 9, 2022
Transactions value $
$41,355
Form type
4
Date filed
6/10/2022, 04:39 PM
Previous filing
May 5, 2022
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Purchase $41.4K +25K +19.79% $1.65 151K Jun 9, 2022 By Armanino Trust F1, F2
holding BTTX Common Stock 13.3K Jun 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BTTX Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 9, 2022 Common Stock 15K $1.66 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.6475 to $1.6791, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 These shares are owned directly by the Andrew J. Armanino III and Denise M. Armanino Family Trust (the "Armanino Trust"), and indirectly by the Reporting Person and his spouse, Denise M. Armanino, as trustees of the Armanino Trust.
F3 The stock option vests in full on the earlier of the first anniversary of the grant date and the Issuer's next annual meeting of stockholders, provided that the Reporting Person continues to serve as a director of the Issuer on such vesting date. The stock option was granted on June 9, 2022.